- Motley Fool•6 days ago
Upcoming FDA decisions could lead to Portola Pharmaceuticals, Puma Biotech, and Tesaro Inc. outperforming Sarepta Therapeutics.
- Capital Cube•6 days ago
Categories: Fundamental Analysis Yahoo Finance Click here to see latest analysis Capitalcube gives Portola Pharmaceuticals, Inc. a score of 29. Our analysis is based on comparing Portola Pharmaceuticals, Inc. with the following peers – Johnson & Johnson, Pfizer Inc., Sanofi Sponsored ADR, Biogen Inc., Bristol-Myers Squibb Company and Tobira Therapeutics, Inc. (JNJ-US, PFE-US, SNY-US, BIIB-US, BMY-US and TBRA-US). Investment Outlook ... Read more (Read more...)
- Forbes•7 days ago
Gilead Sciences has been consistently pressured by analysts to make an acquisition over the past 18 months. The company has been incredibly frugal, stockpiling cash, and avoiding overpaying in an acquisition just to make the analysts happy. They made a bid to purchase Medivation, but lost out to Pfizer. Todd Hagopian says that GILD’s performance the last 15 months (down 34% from it’s high), and it’s huge stockpile of cash (recently bolstered through a $5 billion debt offering), make it unlikely the company will be able to hold off from making a strategic acquisition much longer.
Portola Pharmaceuticals, Inc. (PTLA)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Ask||38.80 x 200|
|Day's Range||23.18 - 23.90|
|52wk Range||18.20 - 52.89|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-5.21|
|Avg Vol (3m)||1,121,814|
|Dividend & Yield||N/A (N/A)|